Paper Details

  1. Home
  2. Paper Details

France Will No More Reimburse Available Symptomatic Drugs Against Alzheimer's Disease.

Author: AmievaHélène, AndrieuSandrine, Delabrousse-MayouxJean-Philippe, DuboisBruno, JeandelClaude, Krolak-SalmonPierre, Perret-LiaudetArmand, SellalFrançois, VandelPierre

EditorialAn article in which the editor or publisher expresses their opinion or perspective on a particular topic or issue. Its purpose is to convey a specific message or idea to the reader.

Overview

This study argues against the French Ministry of Health's decision to remove drugs used to treat Alzheimer's disease from the list of available reimbursed drugs. The authors contend that the evidence-based medicine related to these drugs reaches a high level in the literature and the ratio of benefits/risks favors these drugs.
Paper Details　
Original Abstract of the Article :
The French Minister of Health published a decree on May 29th of 2018 removing the drugs used to fight against symptoms due to Alzheimer's disease (donepezil, rivastigmine, galantamine, memantine) from the list of available reimbursed drugs. This follows the advice delivered by the High Authority for...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3233/JAD-180843

データ提供：米国国立医学図書館（NLM）

France's Decision on Alzheimer's Medications: A Controversial Move

The battle against Alzheimer's disease, a devastating neurodegenerative disorder, is like a relentless desert sandstorm that erodes memories and cognitive function. This article discusses a controversial decision by the French government to remove reimbursement for medications used to treat the symptoms of Alzheimer's disease.

The French Minister of Health made this decision based on recommendations from the High Authority for Health, which cited concerns about the drugs' efficacy and potential side effects. However, many medical professionals strongly disagree with this decision, arguing that these medications offer significant benefits and that the risks are manageable.

A Challenging Decision: Balancing Costs and Benefits

This decision highlights the complexities of healthcare policy, involving balancing cost considerations with the need for effective treatments. It also underscores the ongoing debate surrounding the best ways to manage Alzheimer's disease and its associated symptoms.

Navigating the Desert of Alzheimer's

This research reminds us that Alzheimer's is a challenging disease, and finding effective treatments is a priority. It also highlights the importance of open dialogue and careful consideration of the risks and benefits of different treatment options.

Dr.Camel's Conclusion

This decision is like navigating a treacherous desert path, where choices must be made carefully. It is crucial to continue exploring and developing new treatments for Alzheimer's disease, ensuring that those living with this devastating condition have access to the best possible care and support.

Date :
  1. Date Completed 2019-10-08
  2. Date Revised 2019-10-08
Further Info :

Pubmed ID

30282371

DOI: Digital Object Identifier

10.3233/JAD-180843

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.